{
    "ticker": "IMAB",
    "name": "I-MAB Biopharma",
    "description": "I-MAB Biopharma is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative immuno-oncology therapeutics. Founded in 2010 and headquartered in Shanghai, China, I-MAB is committed to addressing significant unmet medical needs in oncology and autoimmune diseases. The company has established a robust pipeline of proprietary drug candidates, including monoclonal antibodies and antibody-drug conjugates, which target a range of cancers and immune-related disorders. I-MAB collaborates with leading global biopharmaceutical companies to leverage cutting-edge technologies and enhance its research and development capabilities. Their flagship product, TJD5, is a monoclonal antibody that has shown promise in treating various solid tumors. I-MAB is dedicated to advancing the science of immunotherapy, aiming to improve patient outcomes and contribute to the global fight against cancer. With a strong emphasis on innovation, clinical excellence, and strategic partnerships, I-MAB is positioned to become a leader in the biopharma industry.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Shanghai, China",
    "founded": "2010",
    "website": "https://www.i-mabbiopharma.com",
    "ceo": "Dr. Jingwu Zang",
    "social_media": {
        "twitter": "https://twitter.com/I_MAB_Biopharma",
        "linkedin": "https://www.linkedin.com/company/i-mab-biopharma/"
    },
    "investor_relations": "https://www.i-mabbiopharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Jingwu Zang",
            "position": "CEO"
        },
        {
            "name": "Dr. Xiaodong Yang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Monoclonal Antibodies",
            "products": [
                "TJD5",
                "TJD6"
            ]
        },
        {
            "category": "Antibody-Drug Conjugates",
            "products": [
                "IMAB-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "I-MAB Biopharma | Innovative Immuno-Oncology Therapeutics",
        "meta_description": "Explore I-MAB Biopharma, a leading clinical-stage company focused on immuno-oncology and innovative therapeutics. Learn about our pipeline and commitment to patient outcomes.",
        "keywords": [
            "I-MAB",
            "Biopharma",
            "Immuno-Oncology",
            "Monoclonal Antibodies",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What does I-MAB Biopharma specialize in?",
            "answer": "I-MAB Biopharma specializes in the discovery and development of innovative immuno-oncology therapies."
        },
        {
            "question": "What is I-MAB's flagship product?",
            "answer": "I-MAB's flagship product is TJD5, a monoclonal antibody targeting solid tumors."
        },
        {
            "question": "Where is I-MAB headquartered?",
            "answer": "I-MAB is headquartered in Shanghai, China."
        },
        {
            "question": "When was I-MAB founded?",
            "answer": "I-MAB was founded in 2010."
        }
    ],
    "competitors": [
        "BMY",
        "REGN",
        "NVS",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV",
        "MRNA"
    ]
}